US-based small molecule discovery company Receptos secured $10.8m out of a planned $50m series B round last Friday, bringing its total funding to about $43.5m. Investors in the round have not been officially disclosed but signatories for the filing include Receptos board members who are also members of Lilly Ventures, the corporate venturing fund for…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
